1. Scrip
  2. >>Business
  3. >>Deals

Genmab Has First Wholly Owned Antibodies In Phase III, Hunts For More

Shifting From Out-Licensing To Retaining Assets

 
• By Mandy Jackson

CMO Tahamtan Ahmadi told Scrip that Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.

Genmab bought ProfoundBio last year and hopes to sign another deal this year (Shutterstock)

Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, for years the company has been working towards the goal of developing medicines entirely on its own and 2024 was a transformative year in that regard. Now the antibody specialist aims to execute another deal in 2025 that could continue its evolution.

Key Takeaways
  • Genmab has transitioned from primarily out-licensing its antibody candidates to co-developing and co-commercializing them, and now aims to bring forward wholly owned assets on its own.
  • The acquisition of ProfoundBio gave Genmab new ADC capabilities and the ADC Rina-S, one of two wholly owned programs now in Phase III studies

Scrip spoke with Genmab chief medical officer Tahamtan Ahmadi at the J.P. Morgan Healthcare Conference in January about key milestones in the company’s growth and how it plans to build on those efforts this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Scrip

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.